Coronary artery disease and the risk of life-threatening cardiac events after age 40 in long QT syndrome

• Published in: Frontiers in cardiovascular medicine Vol. 11; p. 1418428
• Main Authors: Barsheshet, Alon, Goldenberg, Ilan, Bjelic, Milica, Buturlin, Kirill, Erez, Aharon, Goldenberg, Gustavo, Chen, Anita Y., Polonsky, Bronislava, McNitt, Scott, Aktas, Mehmet, Zareba, Wojciech, Golovchiner, Gregory
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 22.10.2024
• Subjects: Cardiovascular Medicine; coronary artery disease; long QT syndrome; risk factors; sudden cardiac death; ventricular arrhythmia; coronary artery disease; ventricular arrhythmia; risk factors; sudden cardiac death; long QT syndrome
• ISSN: 2297-055X; 2297-055X
• DOI: 10.3389/fcvm.2024.1418428

Long QT syndrome (LQTS) and coronary artery disease (CAD) are both associated with increased risk of ventricular tachyarrhythmia However, there are limited data on the incremental risk conferred by CAD in adult patients with congenital LQTS. We aimed to investigate the risk associated with CAD and life threatening events (LTEs) in patients with LQTS after age 40 years. The risk of LTEs (comprising aborted cardiac arrest, sudden cardiac death, or appropriate defibrillator shock) from age 40 through 75 years was examined in 1,020 subjects from the Rochester LQTS registry, categorized to CAD (  = 137) or no-CAD (  = 883) subgroups. Survival analysis showed that patients with CAD had a significantly higher cumulative event rate of LTEs from 40 to 75 years (35%) compared with those without CAD (7%;  < 0.001 for the overall difference during follow-up). Consistently, multivariate analysis showed that the presence of CAD was associated with a 2.5-fold (HR = 2.47;  = 0.02) increased risk of LTEs after age 40 years. Subgroup analyses showed that CAD vs. no CAD was associated with a pronounced >4-fold (  = 0.008) increased risk of LTEs among LQTS patients with a lower-range QTc (<500 ms). The increased risk of LTEs associated with CAD was not significantly different among the 3 main LQTS genotypes. Patient treatment was suboptimal, with only 63% on β-blockers and 44% on non-selective β-blockers. Our findings suggest that CAD is associated with a higher risk of LTEs in LQTS patients, with the risk being more pronounced in those with QTc <500 ms.